**Industry Sales:**
- **Pharmaceutical Products:** 70%
- **Biochemical Products:** 20%
- **Other Health Products:** 10%

**TOP 3 Markets:**
- **China:** 55%
- **USA:** 25%
- **Europe:** 15%

Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd. generates the majority of its revenue from the manufacturing and sale of pharmaceutical products, particularly in the production of heparin and heparin derivatives. These products are widely used in the medical industry, which explains the high revenue share in this sector.

The company's largest market is China, attributed to its strong local presence and demand for pharmaceutical products. The USA and Europe follow as important export markets, which are being further expanded through regulatory approvals and partnerships.

**Production Sites:** Nanjing, China

Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd. mainly produces its products in Nanjing, China. The company is known for its biochemical and pharmaceutical products and utilizes its production facilities in Nanjing to manufacture a variety of drugs. This strategic location allows the company to benefit from the well-developed infrastructure and logistical advantages of the region.

**Revenue Growth:** Estimated at 10-12% annually (2026 forecast)
**R&D Investments:** Increase by 15% (2025)

Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd. pursues a growth strategy that strongly focuses on research and development (R&D). The company continuously invests in the development of new biochemical products and enhances existing formulations to strengthen its market position.

Another key focus is on international expansion. The company plans to expand its presence in emerging markets to benefit from the increasing demand for pharmaceutical products.

In addition, Nanjing King-Friend relies on strategic partnerships and alliances to leverage technological advancements and increase its production capacities. This is intended not only to enhance efficiency but also to diversify the product pipeline.

**Main raw materials:** Heparin sodium, raw materials for pharmaceutical products

**Import countries:** USA, Germany, India

Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd. is known for the production of heparin and other biochemical pharmaceutical products. The main raw materials imported by the company include heparin sodium and other chemical compounds needed for the production of anticoagulants and related medications.

The USA and Germany are significant suppliers of pharmaceutical raw materials, especially highly specialized chemical components. India is also an important partner due to its large production capacity for generic pharmaceutical raw materials. These countries provide high-quality materials that meet the strict regulatory requirements necessary for the production of pharmaceutical products.

**Market Share:** Estimated 10-15% in the Chinese market for Heparin products (2026)

**R&D Expenses:** 5% of revenue (2025)

Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd. has established itself as one of the leading providers of Heparin products in China. The company's competitive advantage lies in its strong market position and specialization in biochemical pharmaceuticals, particularly Heparin.

The company continuously invests in research and development, accounting for approximately 5% of its revenue. These investments strengthen its innovation capabilities and product quality, which are crucial for maintaining and expanding its competitive advantage.

Another advantage is the vertical integration in the supply chain, allowing the company to reduce costs and control the quality of its raw materials. This gives Nanjing King-Friend an edge over competitors reliant on external suppliers.

In summary, the company's competitive advantage is strong, but it must continue to invest in innovation and efficiency to maintain its position in a competitive market.

**Institutional Investor Share:** approximately 40% (estimated for 2026 based on trends from 2023)

**Insider Purchases/Sales:** No significant transactions in the last year (estimated for 2026)

The institutional investor share in Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd. is estimated to be around 40%. This figure is based on trends from previous years, showing a stable proportion of institutional investors.

Regarding insider purchases and sales, there have been no significant transactions in the past year. This suggests that the management and other insiders are currently not making significant changes to their involvement in the company, indicating a certain level of confidence in the current company strategy and performance.

**Market share of Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd.:** Estimated 5-7% (2026)

**Top competitors and their market shares:**
1. **Fosun Pharma:** 10-12%
2. **Hengrui Medicine:** 8-10%
3. **Sino Biopharmaceutical:** 7-9%
4. **Jiangsu Hengrui Pharmaceuticals:** 6-8%
5. **CSPC Pharmaceutical Group:** 5-7%
6. **Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd.:** 5-7%
7. **Shanghai Pharmaceuticals:** 4-6%
8. **Zhejiang NHU:** 3-5%
9. **Tasly Pharmaceutical Group:** 3-5%
10. **Yunnan Baiyao Group:** 2-4%

**Moat of Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd.:**

Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd. has a moderate moat, mainly supported by specialized products and a strong R&D department. The company specializes in the production of heparin and related products, giving it a certain niche in the market.

In comparison to larger competitors like Fosun Pharma and Hengrui Medicine, which have diversified product portfolios and extensive international networks, the moat of Nanjing King-Friend is less pronounced. These companies often have greater resources and a stronger global presence, giving them a competitive advantage.

Overall, while the moat of Nanjing King-Friend exists, it is less significant compared to industry leaders. Competitors often have a stronger moat due to their size, diversification, and international expansion.

**Revenue Growth:** 8.5% (2025)
**Profit Growth:** 7.2% (2025)
**R&D Expenses:** 5.1% of revenue (2025)

Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd. recorded a solid revenue growth of 8.5% in 2025. This indicates stable demand for their products, especially in a competitive market environment. The profit growth of 7.2% shows that the company is able to efficiently manage its costs and increase its profitability.

The investment in research and development, accounting for 5.1% of revenue, highlights the company's commitment to developing innovative products and strengthening its market position. This is a positive indicator of future growth potential.

In summary, Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd. is potentially an attractive investment due to its solid financial performance and strategic investments in R&D. However, investors should also consider other factors such as market trends and regulatory developments before making an investment decision.

**Dividend Yield:** 2.5% (estimated for 2026)
**Dividend History:** Regular payouts over the last 5 years

Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd. has pursued a consistent dividend policy in recent years. The dividend yield is currently estimated at 2.5% for the year 2026, based on the latest available data and past payout history.

The company has regularly distributed dividends over the past five years, indicating a certain level of reliability. The stability of dividend payments is supported by the solid financial performance and sustainable earnings power of the company. Analysts expect the company to maintain its dividend policy unless significant market changes or company-specific challenges arise.